Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin SensitizerJerry R. Colca, David G. Orloff, Wade J. Adams et al.|Clinical Pharmacology & Therapeutics|2013Cited by 83